Alkermes Plc (ALKS) Holder Marsico Capital Management Has Decreased Position by $1.34 Million; Cortina Asset Management Has Boosted Pacira Pharmaceuticals (PCRX) Stake by $1.13 Million; Share Price Rose

November 15, 2017 - By Henry Gaston

Cortina Asset Management Llc increased its stake in Pacira Pharmaceuticals Inc (PCRX) by 10.92% based on its latest 2017Q2 regulatory filing with the SEC. Cortina Asset Management Llc bought 24,014 shares as the company’s stock rose 10.53% with the market. The institutional investor held 243,860 shares of the health care company at the end of 2017Q2, valued at $11.63 million, up from 219,846 at the end of the previous reported quarter. Cortina Asset Management Llc who had been investing in Pacira Pharmaceuticals Inc for a number of months, seems to be bullish on the $1.62 billion market cap company. It closed at $39.92 lastly. It is down 12.40% since November 15, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Marsico Capital Management Llc decreased its stake in Alkermes Plc (ALKS) by 37.14% based on its latest 2017Q2 regulatory filing with the SEC. Marsico Capital Management Llc sold 23,544 shares as the company’s stock rose 6.12% with the market. The institutional investor held 39,854 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $2.31 million, down from 63,398 at the end of the previous reported quarter. Marsico Capital Management Llc who had been investing in Alkermes Plc for a number of months, seems to be less bullish one the $7.33B market cap company. It closed at $47.69 lastly. It is down 47.50% since November 15, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.




More notable recent Alkermes Plc (NASDAQ:ALKS) news were published by: Prnewswire.com which released: “ACT NOW: Monteverde & Associates PC Announces an Investigation of Alkermes plc …” on November 11, 2017, also Streetinsider.com with their article: “Alkermes plc (ALKS) Launches Investigational Product Designed for Initiation …” published on October 26, 2017, Streetinsider.com published: “Alkermes plc (ALKS) Reports Positive Preclinical Data for ALKS 4230 Presented …” on November 08, 2017. More interesting news about Alkermes Plc (NASDAQ:ALKS) were released by: Businesswire.com and their article: “Alkermes plc Reports Third Quarter 2017 Financial Results” published on October 26, 2017 as well as Seekingalpha.com‘s news article titled: “Alkermes Stands To Gain From Revenue Increase, Upcoming NDA Submission” with publication date: October 16, 2017.

Investors sentiment increased to 1.12 in Q2 2017. Its up 0.01, from 1.11 in 2017Q1. It improved, as 33 investors sold ALKS shares while 72 reduced holdings. 41 funds opened positions while 77 raised stakes. 143.16 million shares or 1.87% more from 140.52 million shares in 2017Q1 were reported. Cornerstone holds 732 shares or 0.02% of its portfolio. Global X has invested 0% in Alkermes Plc (NASDAQ:ALKS). Texas-based Automobile Association has invested 0.03% in Alkermes Plc (NASDAQ:ALKS). Tocqueville Asset Mgmt Ltd Partnership reported 373,891 shares or 0.26% of all its holdings. Daiwa Sb Invests holds 2,865 shares. Jacobs Levy Equity reported 0.01% in Alkermes Plc (NASDAQ:ALKS). First Trust Lp holds 0.15% or 979,813 shares in its portfolio. Numeric Invsts Ltd Co accumulated 8,600 shares or 0% of the stock. Cibc Asset stated it has 6,090 shares or 0% of all its holdings. Winfield owns 40 shares. Moreover, Weiss Multi has 0.02% invested in Alkermes Plc (NASDAQ:ALKS) for 10,000 shares. Fifth Third National Bank & Trust holds 0% of its portfolio in Alkermes Plc (NASDAQ:ALKS) for 17 shares. 14,922 are held by Nuveen Asset Ltd. Sg Americas Ltd Liability Corporation accumulated 8,381 shares or 0% of the stock. Pennsylvania-based Nationwide Fund Advsrs has invested 0% in Alkermes Plc (NASDAQ:ALKS).

Analysts await Alkermes Plc (NASDAQ:ALKS) to report earnings on February, 21. They expect $-0.01 EPS, up 75.00% or $0.03 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Alkermes Plc for the previous quarter, Wall Street now forecasts -88.89% EPS growth.

Among 13 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Alkermes had 33 analyst reports since September 1, 2015 according to SRatingsIntel. On Thursday, August 24 the stock rating was maintained by Jefferies with “Buy”. Jefferies maintained Alkermes Plc (NASDAQ:ALKS) on Friday, July 29 with “Buy” rating. The rating was downgraded by Barclays Capital to “Equal-Weight” on Monday, October 16. The stock of Alkermes Plc (NASDAQ:ALKS) has “Market Perform” rating given on Tuesday, July 26 by Cowen & Co. As per Friday, October 20, the company rating was maintained by Mizuho. Cantor Fitzgerald maintained the shares of ALKS in report on Thursday, July 27 with “Hold” rating. The firm has “Overweight” rating given on Tuesday, September 1 by Morgan Stanley. The stock of Alkermes Plc (NASDAQ:ALKS) has “Overweight” rating given on Friday, October 21 by JP Morgan. Jefferies maintained Alkermes Plc (NASDAQ:ALKS) on Tuesday, September 26 with “Buy” rating. The company was maintained on Thursday, January 21 by Leerink Swann.

Marsico Capital Management Llc, which manages about $17.14 billion and $2.39B US Long portfolio, upped its stake in Ryanair Hldgs Plc by 5,054 shares to 130,985 shares, valued at $14.10M in 2017Q2, according to the filing. It also increased its holding in Apple Inc (NASDAQ:AAPL) by 67,316 shares in the quarter, for a total of 328,746 shares, and has risen its stake in Ball Corp (NYSE:BLL).

Investors sentiment increased to 1.62 in 2017 Q2. Its up 0.45, from 1.17 in 2017Q1. It increased, as 23 investors sold PCRX shares while 45 reduced holdings. 37 funds opened positions while 73 raised stakes. 39.35 million shares or 1.09% less from 39.78 million shares in 2017Q1 were reported. 40 North Management Ltd Limited Liability Company stated it has 2.73% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Moreover, Raymond James has 0% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Avenir Corporation stated it has 10,020 shares or 0.04% of all its holdings. Suntrust Banks invested in 0% or 14,328 shares. Tower Llc (Trc) has 100 shares. Balyasny Asset Ltd Liability Corporation holds 0.04% or 202,209 shares in its portfolio. Automobile Association invested in 0.01% or 91,800 shares. 240 are owned by Vantage Limited Liability Company. Oppenheimer Asset Management has 0% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 2,399 shares. Schroder Inv Mngmt Group holds 0.08% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 935,168 shares. Fifth Third Comml Bank stated it has 1,862 shares or 0% of all its holdings. 1,026 are held by Equitec Specialists Lc. 6,257 are owned by Fisher Asset Management Limited Liability Company. California-based Schwab Charles Invest Mgmt has invested 0.01% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). 26,681 are owned by Metropolitan Life Insurance Communications.

Among 19 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 11 have Buy rating, 1 Sell and 7 Hold. Therefore 58% are positive. Pacira Pharmaceuticals had 70 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Buy” rating by Piper Jaffray on Wednesday, November 8. On Wednesday, February 22 the stock rating was initiated by Canaccord Genuity with “Buy”. As per Wednesday, June 21, the company rating was maintained by Wedbush. On Thursday, November 9 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The rating was maintained by BMO Capital Markets with “Hold” on Wednesday, November 8. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Mkt Outperform” rating given on Tuesday, January 5 by JMP Securities. Wedbush maintained Pacira Pharmaceuticals Inc (NASDAQ:PCRX) rating on Tuesday, July 25. Wedbush has “Buy” rating and $8700 target. The firm has “Buy” rating given on Wednesday, December 21 by Mizuho. On Monday, August 21 the stock rating was upgraded by Janney Capital to “Neutral”. The company was downgraded on Thursday, October 26 by Janney Capital.

Since June 5, 2017, it had 0 insider purchases, and 7 sales for $495,424 activity. Braunstein Scott had sold 768 shares worth $33,271 on Monday, June 5. The insider Scibetta James S sold $85,169. Jones James B sold $33,227 worth of stock or 767 shares. $81,314 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was sold by Williams Kristen Marie. STACK DAVID M had sold 4,311 shares worth $186,757.

More notable recent Pacira Pharmaceuticals Inc (NASDAQ:PCRX) news were published by: Marketwired.com which released: “Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results” on November 08, 2017, also Fool.com with their article: “The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much …” published on November 08, 2017, Prnewswire.com published: “Breakfast Technical Briefing on Generic Drugs Stocks — Mallinckrodt, Akorn …” on November 10, 2017. More interesting news about Pacira Pharmaceuticals Inc (NASDAQ:PCRX) were released by: Globenewswire.com and their article: “Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement” published on October 25, 2017 as well as Globenewswire.com‘s news article titled: “Pacira Pharmaceuticals to Present at Two November Healthcare Conferences” with publication date: October 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts